Clinical Trial Detail

NCT ID NCT03040973
Title Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving INC280 Treatment as Single Agent or in Combination With Other Treatments.
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Capmatinib + Nazartinib

Capmatinib

Capmatinib + Gefitinib

Age Groups: adult child senior

No variant requirements are available.